Nephrology focuses on diagnosing and treating kidney diseases. The kidneys filter waste, balance fluids, regulate blood pressure, and manage acute and chronic conditions.
Send us all your questions or requests, and our expert team will assist you.
The diagnosis and evaluation of Hemolytic Uremic Syndrome (HUS) requires a coordinated approach that blends clinical insight with targeted laboratory and imaging studies. International patients arriving at Liv Hospital can expect a seamless pathway from initial assessment to definitive diagnosis, ensuring timely treatment and optimal outcomes. HUS affects approximately 1 in 5,000 children annually, and early recognition dramatically reduces the risk of permanent kidney damage.
Our multidisciplinary team, comprising nephrologists, hematologists, and radiologists, follows evidence‑based protocols to identify the syndrome quickly while ruling out conditions with overlapping features. This page outlines each step of the diagnostic journey, from the first bedside evaluation to advanced genetic testing, helping patients and families understand what to expect during their stay in Istanbul.
By integrating state‑of‑the‑art technology with compassionate care, Liv Hospital delivers a thorough diagnostic workup that supports personalized treatment plans for both pediatric and adult patients affected by HUS.
Recognizing the hallmark signs of HUS is the cornerstone of a successful diagnostic and evaluation process. Patients typically present with a triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. However, the spectrum of symptoms can vary widely depending on age, underlying cause, and disease severity.
During the initial assessment, physicians record vital signs, perform a focused physical examination, and obtain a detailed medical history, including recent infections, medication exposure, and travel. This information guides the selection of subsequent laboratory and imaging studies.
Prompt recognition of these clinical cues accelerates the overall diagnosis and evaluation timeline, allowing for early intervention that can preserve kidney function.
Laboratory testing provides the objective data needed to confirm HUS and to differentiate it from other thrombotic microangiopathies. A comprehensive panel is ordered at presentation and repeated to track disease progression.
In addition to the core panel, specific assays such as stool culture for Shiga toxin, serum complement levels, and ADAMTS13 activity are ordered when the clinical picture suggests atypical or secondary HUS. These targeted tests refine the diagnostic and evaluation pathway and guide therapeutic decisions.
While laboratory data remain primary, imaging modalities provide essential information about organ involvement and help exclude alternative diagnoses. Liv Hospital employs a range of non‑invasive techniques to visualize renal and systemic changes.
Several thrombotic microangiopathies share clinical and laboratory features with HUS, making a careful differential diagnosis essential. Accurate distinction influences both prognosis and treatment choice.
By systematically applying this algorithm, clinicians at Liv Hospital achieve a precise diagnosis and evaluation, ensuring that each patient receives the most appropriate therapy—whether plasma exchange for TTP, eculizumab for aHUS, or supportive care for classic Shiga‑toxin HUS.
When routine work‑up points toward an atypical presentation, specialized assays become indispensable. Liv Hospital’s advanced laboratory facilities can perform these high‑complexity tests with rapid turnaround times, a vital factor in acute care settings.
This test quantifies the activity of the von Willebrand factor‑cleaving protease. Values below 10 % are diagnostic for TTP, whereas normal or mildly reduced levels support an HUS diagnosis.
Stool samples are examined using polymerase chain reaction (PCR) or enzyme‑linked immunosorbent assay (ELISA) to identify Shiga‑producing Escherichia coli (STEC). A positive result confirms typical, infection‑related HUS.
Patients with suspected aHUS undergo next‑generation sequencing panels that target genes such as CFH, CFI, CD46, and C3. Identification of pathogenic variants guides the use of complement inhibitors.
Liv Hospital combines JCI accreditation with a dedicated international patient program, ensuring that every step of the diagnosis and evaluation process is coordinated across language, culture, and medical expertise. Our nephrology unit offers cutting‑edge laboratory services, on‑site radiology, and a team fluent in multiple languages to support seamless communication. International patients benefit from personalized logistics—including airport transfers, interpreter services, and comfortable accommodation—so they can focus on recovery while we handle the complexities of care.
Ready to begin your comprehensive evaluation for Hemolytic Uremic Syndrome? Contact Liv Hospital today to schedule a consultation with our expert nephrology team and take the first step toward personalized, world‑class care.
Liv Hospital Vadistanbul
Prof. MD. Süleyman Tevfik Ecder
Nephrology
Liv Hospital Bahçeşehir
Asst. Prof. MD. Himmet Bora Uslu
Nephrology
Liv Hospital Bahçeşehir
Prof. MD. Mehmet Taşdemir
Pediatric Nephrology
Liv Hospital Bahçeşehir
Prof. MD. Ozan Özkaya
Pediatric Nephrology
Liv Hospital Ankara
Prof. MD. Hüsnü Oğuz Söylemezoğlu
Pediatric Nephrology
Liv Bona Dea Hospital Bakü
MD. FERHAD ŞİRİNOV
Nephrology
Send us all your questions or requests, and our expert team will assist you.
Patients with Hemolytic Uremic Syndrome typically present with a sudden onset of fatigue and pallor due to anemia, dark-colored urine or hematuria indicating renal involvement, and easy bruising or petechiae reflecting low platelet counts. Gastrointestinal symptoms such as abdominal pain or bloody diarrhea are common in Shiga‑toxin associated cases. Neurological manifestations can range from mild confusion to seizures in severe disease. Vital signs may reveal hypertension secondary to renal impairment, and a focused neurological exam helps detect early central nervous system involvement. Collecting a detailed history of recent infections, medication exposure, or travel is essential to guide further testing.
The initial laboratory work‑up for HUS starts with a complete blood count and peripheral smear to identify schistocytes, confirming microangiopathic hemolysis, and to quantify anemia and thrombocytopenia. Renal function is assessed with serum creatinine and blood urea nitrogen levels, while lactate dehydrogenase is markedly elevated in hemolysis. Haptoglobin is usually reduced, and a coagulation profile (PT, aPTT, fibrinogen) helps exclude disseminated intravascular coagulation. When the clinical picture suggests an infectious trigger, stool PCR or ELISA for Shiga toxin is ordered. Complement levels and ADAMTS13 activity are measured to differentiate atypical HUS, TTP, and other thrombotic microangiopathies.
While laboratory data provide the primary diagnosis, imaging offers critical information about the extent of organ damage and helps exclude alternative conditions. Renal ultrasonography is the first‑line modality, revealing increased cortical echogenicity suggestive of acute tubular injury and confirming the absence of hydronephrosis. CT angiography is reserved for suspected vascular thrombosis or renal infarction, whereas MRI with diffusion‑weighted sequences evaluates cerebral involvement without radiation exposure. A chest X‑ray screens for pulmonary edema secondary to fluid overload. Integrating these imaging findings with lab results creates a comprehensive picture of disease severity, guiding therapeutic decisions.
Differential diagnosis relies on a combination of specific tests and clinical context. An ADAMTS13 activity assay below 10 % is diagnostic for thrombotic thrombocytopenic purpura, while normal or mildly reduced levels support HUS. Positive stool Shiga toxin PCR confirms typical, infection‑related HUS. Low complement C3/C4 with normal ADAMTS13 points toward atypical HUS driven by complement dysregulation. Prolonged PT/aPTT and low fibrinogen indicate disseminated intravascular coagulation. Applying this decision‑tree enables clinicians at Liv Hospital to select the appropriate therapy, such as plasma exchange for TTP or eculizumab for aHUS.
International patients benefit from Liv Hospital’s dedicated program that handles logistics from arrival to discharge. Services include airport pick‑up, multilingual interpreters, and assistance with visa and accommodation arrangements. The nephrology unit integrates on‑site radiology, advanced laboratory services, and a team of nephrologists, hematologists, and radiologists fluent in several languages. This coordinated approach ensures that language barriers do not delay the diagnostic work‑up, allowing patients and families to focus on treatment and recovery while the hospital manages the complexities of care.
BlogHemolytic UremicMay 07, 2026Discover the essential steps to treat HUS and regain your health. Our comprehensive guide covers the latest...
BlogHemolytic UremicMay 07, 2026Get informed about HUS disease - learn the 5 crucial facts to know about this rare but critical health cond...
BlogHemolytic UremicMay 07, 2026Learn about erythroblastosis fetalis, a dangerous condition where maternal antibodies attack fetal red bloo...
BlogHemolytic UremicMay 07, 2026Understanding your body’s inner workings is key to good health. At Liv Hospital, we think knowing is ...
BlogHemolytic UremicApr 14, 2026Learn the essential steps to identify and manage intravascular hemolysis for optimal patient outcomes.
BlogHemolytic UremicApr 14, 2026Discover the 7 key symptoms of HUS, the dangerous E. coli complication. Our article provides a comprehensiv...
Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.
Start Chat on WhatsApp or call us at +90 530 174 28 17